Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05251389RecruitingPhase 1/Phase 2
Fecal microbiome transplant after anti-PD-1 melanoma not working
This trial tests whether a fecal microbiome transplant (FMT) can help your body respond better to anti-PD-1 immunotherapy in advanced skin melanoma. It is for people whose melanoma has progressed despite anti-PD-1 treatment.
AmsterdamAges 18 years+ - NCT07320105RecruitingPhase 4
Radiation after surgery for lung cancer that spread to lymph nodes
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
Fuzhou, FujianAges 18–75 - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07307833Enrolling by invitation
Immune therapy and its effect on balance
This study checks if certain immune therapy drugs affect your balance or inner ear function. It involves people starting treatment with one or two of these drugs for cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07311408RecruitingPhase 2
New drug combo for stomach cancer after immunotherapy
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
Shenyang, LiaoningAges 18 years+ - NCT07311083Recruiting
Lifestyle program for triple-negative breast cancer patients
This study tests a lifestyle program (diet, exercise, and support) for women with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. The goal is to see if healthy habits can help during treatment.
Essen, North Rhine-WestphaliaAges 18–75 - NCT06521866RecruitingPhase 2
Study of serplulimab plus standard therapy for advanced colorectal cancer
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Fuzhou, FujianAges 18 years+ - NCT06567353Recruiting
Heat-based immunotherapy for breast cancer liver metastases
This trial tests a new treatment that uses heat to target liver tumors and boost the immune system. It is for women with breast cancer that has spread to the liver who cannot have or do not want surgery.
ShanghaiAges 18–75 - NCT07302607Recruiting
Melanoma immunotherapy study at Strasbourg Hospital
This study looks back at medical records to find out what factors helped people with advanced melanoma respond completely to immunotherapy. It includes patients treated at a specific hospital in France between 2013 and 2021.
StrasbourgAges 18 years+ - NCT06635954Recruiting
Blood test to predict response to immunotherapy
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Norwich, ConnecticutAges 18 years+ - NCT07290153Recruiting
Psychological health and immunotherapy for TNBC
This study looks at how psychological factors and the immune system affect treatment response in women with triple-negative breast cancer. Researchers will use questionnaires and biological samples to understand these links.
Shanghai, Please SelectAges 18–70 - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07291921Recruiting
Blood tests before and after lung cancer surgery
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
Beijing, Beijing MunicipalityAges 18–85 - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT07291947RecruitingPhase 1/Phase 2
Radiation plus immunotherapy and chemotherapy for bile duct cancer
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
Chengdu, SichuanAges 18–75 - NCT07288112RecruitingPhase 1/Phase 2
Immunotherapy using your own cells for advanced melanoma
This study tests an experimental treatment made from your own immune cells. The cells are collected, trained in the lab to recognize your melanoma, and then injected near your lymph nodes to help your immune system fight the cancer. This is for people whose melanoma has not responded to standard immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07286331RecruitingPhase 3
New drug vs chemo for advanced endometrial cancer
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
Birmingham, AlabamaAges 18 years+ - NCT07281716RecruitingPhase 1/Phase 2
Immunotherapy combo for advanced colorectal cancer
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06880029RecruitingPhase 1/Phase 2
Timing of chemo and immunotherapy for breast cancer
This trial is testing whether the time of day you receive chemotherapy and pembrolizumab (immunotherapy) affects how well they work against triple-negative breast cancer. It's for people who will get these treatments before surgery.
Vila Nova de Gaia, RegiãoAges 18–75 - NCT06889649RecruitingPhase 2
SBRT plus immunotherapy and targeted therapy for kidney cancer
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT05832606Recruiting
Food changes to reduce side effects from immunotherapy
This trial tests whether a specific food plan can reduce side effects (toxicity) from standard immunotherapy that targets PD-1 and/or CTLA-4. It may help people tolerate treatment better while staying on their usual cancer care.
JetteAges 18 years+ - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.